Last reviewed · How we verify
Epinephrine 1/1000
Epinephrine 1/1000 is a Catecholamine; adrenergic agonist Small molecule drug developed by Ministry of Health, Spain. It is currently in Phase 3 development for Anaphylaxis (acute allergic reaction), Cardiac arrest (cardiopulmonary resuscitation), Severe hypotension/shock. Also known as: Adrenaline 1/1000, Adrenalin 1/1000.
Epinephrine is a catecholamine that activates alpha and beta adrenergic receptors to increase heart rate, blood pressure, and bronchial dilation.
Epinephrine is a catecholamine that activates alpha and beta adrenergic receptors to increase heart rate, blood pressure, and bronchial dilation. Used for Anaphylaxis (acute allergic reaction), Cardiac arrest (cardiopulmonary resuscitation), Severe hypotension/shock.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Epinephrine 1/1000 |
|---|---|
| Also known as | Adrenaline 1/1000, Adrenalin 1/1000 |
| Sponsor | Ministry of Health, Spain |
| Drug class | Catecholamine; adrenergic agonist |
| Target | Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Emergency Medicine; Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Epinephrine binds to alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors on target tissues. This activation increases cardiac contractility and heart rate (beta-1), causes vasoconstriction (alpha-1), and promotes bronchial smooth muscle relaxation (beta-2). These combined effects rapidly restore blood pressure and tissue perfusion during anaphylaxis or cardiac arrest.
Approved indications
- Anaphylaxis (acute allergic reaction)
- Cardiac arrest (cardiopulmonary resuscitation)
- Severe hypotension/shock
- Acute bronchospasm
Common side effects
- Tachycardia
- Hypertension
- Tremor
- Anxiety/nervousness
- Headache
- Palpitations
- Arrhythmias
Key clinical trials
- First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics (PHASE1)
- Antibiotyping and Prevalence of Virulent Genotypes Among Helicobacter Pylori and Their Impact on Response to Therapy (NA)
- Effect of Extracorporeal Shockwave Therapy on Pruritus in Neurodermatitis Patients (NA)
- Prospective Evaluation of Efficacy of Tumescent Steroid Infiltration in Mandibular Third Molar Surgery: a Split Mouth Randomized Study (NA)
- Opioid-Free Pain Protocol After Shoulder Arthroplasty (PHASE4)
- Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer (PHASE2)
- Dilute Epinephrine vs Tourniquet for Visualization in Ankle Arthroscopy: A RCT (NA)
- WALANT Versus Local Anesthesia in Central Venous Catheter Insertion (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Epinephrine 1/1000 CI brief — competitive landscape report
- Epinephrine 1/1000 updates RSS · CI watch RSS
- Ministry of Health, Spain portfolio CI
Frequently asked questions about Epinephrine 1/1000
What is Epinephrine 1/1000?
How does Epinephrine 1/1000 work?
What is Epinephrine 1/1000 used for?
Who makes Epinephrine 1/1000?
Is Epinephrine 1/1000 also known as anything else?
What drug class is Epinephrine 1/1000 in?
What development phase is Epinephrine 1/1000 in?
What are the side effects of Epinephrine 1/1000?
What does Epinephrine 1/1000 target?
Related
- Drug class: All Catecholamine; adrenergic agonist drugs
- Target: All drugs targeting Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors
- Manufacturer: Ministry of Health, Spain — full pipeline
- Therapeutic area: All drugs in Emergency Medicine; Cardiovascular
- Indication: Drugs for Anaphylaxis (acute allergic reaction)
- Indication: Drugs for Cardiac arrest (cardiopulmonary resuscitation)
- Indication: Drugs for Severe hypotension/shock
- Also known as: Adrenaline 1/1000, Adrenalin 1/1000
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing